Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration.
Terpos
Evangelos
E
Department of Haematology, Faculty of Medicine Imperial College, Hammersmith Hospital, Du Cane Road, W12 0NN London, UK.
Politou
Marianna
M
Rahemtulla
Amin
A
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001897:Boronic Acids / Q000009:adverse effects*; D000069286:Bortezomib; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000009:adverse effects*; D015275:Tumor Lysis Syndrome / Q000209:etiology*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib